Strain Data Sheet

RBRC01707

Strain Information

Image
BRC No.RBRC01707
TypeTransgeneCartagena
SpeciesMus musculus
Strain nameB6.Cg-Tg(Mt1-RET)192Ina
Former Common name192 RET
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain developmentDeveloped by Masashi Kato, Nagoya University Graduate School of Medicine. The transgene was injected into the pronuclei of (BALB/c x C57BL/6) x BALB/c fertilized eggs. C57BL/6 and BALB/c mixed background.
Strain descriptionThis strain expresses the human RET gene under the control of the mouse Mt1 promoter/enhancer. This Mt1-RET 192 line develops benign tumors 100% within several months after birth. However they never transform to malignant tumors. Crossing with C57BL/6 multiple times makes this strain more difficult to maintain because of the earlier onset of tumors.
Colony maintenanceCarrier x Noncarrier
References
Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene.
Iwamoto T, Takahashi M, Ito M, Hamatani K, Ohbayashi M, Wajjwalku W, Isobe K, Nakashima I
EMBO J., 10, 3167-3175 (1991). 1915289

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
SV40 splicing signal-polyadenylation siteUN
RETrecombinant RET proto-oncogene (human)UNRETmouse metallothionein 1 promoter/enhancer
Tg(Mt1-RET)192Inatransgene insertion 192, Izumi NakashimaUNTg(Mt1-RET)192Ina

Phenotype

Annotation by Mammalian phenotyhpe ontology
  • hyperpigmentation(MP:0001188)

  • increased cutaneous melanoma incidence(MP:0010322)

  • increased ear pigmentation(MP:0011278)

  • increased melanoma incidence(MP:0010275)

  • increased tail pigmentation(MP:0011276)
    • more 1 phenotypes
  • thick tail(MP:0000588)
    • Detailed phenotype data

    Ordering Information

    Donor DNAhuman RFP/RET cDNA, mouse MT-I promoter-enhancer, SV40 splicing signal-polyadenylation site, vector sequence
    Research applicationCancer Research
    Dermatology Research
    Mouse Models for Human Disease
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR.
    DepositorMasashi Kato (Chubu University)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data